Skip to Content

Metaproterenol Pregnancy and Breastfeeding Warnings

Metaproterenol is also known as: Alupent, Metaprel

Medically reviewed on Jul 23, 2018

Metaproterenol Pregnancy Warnings

Metaproterenol has been assigned to pregnancy category C by the FDA. Reproductive studies in mice and rabbits have demonstrated teratogenic and embryotoxic effects at doses at least 30 times the normal human oral dose. There are no controlled data in human pregnancy, although it has been used systemically to inhibit preterm labor. No fetal abnormalities have been reported with such use, however, the fetus may experience the general adverse effects reported in the mother. Use of metaproterenol in pregnant women for the relief of bronchospasm may interfere with uterine contractility. Metaproterenol is only recommended for use during pregnancy when benefit outweighs risk.

See references

Metaproterenol Breastfeeding Warnings

There are no data on the excretion of metaproterenol into human milk. The manufacturer recommends that caution be used when administering metaproterenol to nursing women.

See references

References for pregnancy information

  1. "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.
  2. Baillie P, Meehan FP, Tyack AJ "Treatment of premature labour with orciprenaline." Br Med J 4 (1970): 154-5
  3. Zilianti M, Aller J "Action of orciprenaline on uterine contractility during labor, maternal cardiovascular system, fetal heart rate, and acid-base balance." Am J Obstet Gynecol 109 (1971): 1073-9

References for breastfeeding information

  1. "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.